DE

latest development

Investor Relations

Investment History

  • US $ 20.8 Invested by private investors from 2012 (Founders & VCs)
  • US $ 4.9 Invested by CSO and Innovation Authorities (Non dilutive Grants)
  • In 2019 Max Herzberg and Yochai Richter acquired all shares of the VC group as a management buy out 
  • From 2019 the company is funded by shareholders and management's investments, mainly by Max Herzberg and Yochai Richter
  • Listed in Hamburg and Stuttgart Stock Exchanges and upgrading to main Bafin authorized German exchange (in process) for further major funding (Phase 2 and 3 for previous projects and present application)
  • Winner of Seal of excellence from Horizon Europe EIC
Analyst Report

Vidac Pharma Analyst Report follow-up Nov. 2024

Download

Vidac Pharma Analyst Report follow-up July 2024

Download

Vidac Pharma  Analyst report June 2024

Download

Financial Statements

Unaudited 30 June 2024 Financial Statements

Download

 

December 31 2023 Financial Statement

Download

30 June 2023 Financial Statement

Download

31 December 2022 Financial Statement

Download

6 Month Financial Statements 2022

Download

31 December 2021 Financial Statement

Download

Dr. Max Herzberg
      20-22 Wenlock Road
      London N1 7GU
      United Kingdom
+972 (0)779300647
Total number of issued shares is 51,625,062
TRADING SYMBOL: T9G
WKN: A3DTUQ
ISIN: GB00BM9XQ619
LEI: 875500BCH1T6XX5EUG13

Disclaimer

The following information does not constitute an public offer to sell or a solicitation to submit an offer to buy or subscribe to shares of Vidac Pharma Holding PLC, but is for informational purposes only.